Abstract
Increasing evidence revealed that miRNAs, the vital regulators of gene expression, are involved in various cellular processes, including cell growth, differentiation, apoptosis and progression. In addition, miRNAs act as oncogenes and/or tumor suppressors. The present study aimed to verify the potential roles of miR148b in human renal cancer cells. miR‑148b was found to be downregulated in human renal cancel tissues and human renal cancer cell lines. Functional studies demonstrated that plasmid‑mediated overexpression of miR‑148b promoted cell proliferation, increased the S‑phase population of the cell cycle and enhanced apoptosis in the 786‑O and OS‑RC‑2 renal cancer cell lines, while it did not appear to affect the total number of viable cells according to a Cell Counting Kit‑8 assay. Subsequently, a luciferase reporter assay verified that miR148b directly targeted mitogen‑activated protein kinase (MAPK) kinase kinase 9 (MAP3K9), an upstream activator of MAPK kinase/c‑Jun N‑terminal kinase (JNK) signaling, suppressing the protein but not the mRNA levels. Furthermore, western blot analysis indicated that overexpression of miR148b in renal cancer cells inhibited MAPK/JNK signaling by decreasing the expression of phosphorylated (p)JNK. In addition, overexpression of MAP3K9 and pJNK was detected in clinical renal cell carcinoma specimens compared with that in their normal adjacent tissues. The present study therefore suggested that miR‑148b exerts an oncogenic function by enhancing the proliferation and apoptosis of renal cancer cells by inhibiting the MAPK/JNK pathway.
Introduction
Renal cell carcinoma (RCC) represents a significant clinical challenge as the most lethal common urological malignancy. Its increasing global incidence necessitates a deeper understanding of the molecular mechanisms driving its progression to identify novel diagnostic and prognostic biomarkers. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression post-transcriptionally, have emerged as key players in cancer biology. While miR-148b is recognized as a tumor suppressor in several malignancies, its role in RCC has remained largely unexplored. This study investigates the expression profile and functional impact of miR-148b in renal cancer, specifically its interaction with the MAP3K9/JNK signaling pathway.
Methods
The researchers utilized 12 pairs of human renal clear cell carcinoma tissues and adjacent normal tissues for clinical validation. In vitro experiments were conducted using 786-O and OS-RC-2 renal cancer cell lines, with 293T cells as a normal control. miR-148b was overexpressed using plasmid-mediated mimics. Target verification was achieved through TargetScan bioinformatics prediction and dual-luciferase reporter assays. Functional consequences were assessed via CCK-8 (viability), EdU staining (proliferation), and Annexin V/PI flow cytometry (apoptosis). Pathway analysis was performed using western blotting to measure phosphorylated JNK (pJNK) levels.
Results
miR-148b is Downregulated in Renal Cancer
Initial assessments revealed that miR-148b expression is significantly reduced in clinical RCC specimens compared to adjacent normal tissues. This downregulation was mirrored in renal cancer cell lines (786-O and OS-RC-2) relative to the normal 293T cell line ($P < 0.05$).
Functional Impact: The Proliferation-Apoptosis Paradox
Restoration of miR-148b levels led to a paradoxical outcome. While total cell viability (measured by CCK-8) remained largely unchanged, functional assays revealed that miR-148b significantly increased both cell proliferation (S-phase entry) and programmed cell death (apoptosis). This suggests that miR-148b accelerates cellular turnover rather than simply inhibiting or promoting net growth.
Direct Targeting of MAP3K9 and JNK Pathway Inhibition
Luciferase reporter assays confirmed that miR-148b directly binds to the 3'UTR of MAP3K9 mRNA. Interestingly, miR-148b suppressed MAP3K9 at the protein level without affecting its mRNA levels, indicating post-transcriptional silencing. Furthermore, overexpression of miR-148b resulted in decreased levels of phosphorylated JNK (pJNK), effectively inhibiting the MAPK/JNK signaling cascade. In clinical samples, low miR-148b levels correlated with high expression of MAP3K9 and pJNK.
Discussion
This study identifies miR-148b as a complex regulator in RCC. By targeting MAP3K9, miR-148b modulates the JNK pathway, which is known for its dual role in promoting both survival and apoptosis. The observed increase in both proliferation and death upon miR-148b restoration highlights the nuanced regulatory landscape of miRNAs. While the study is limited by a small clinical sample size and a lack of in vivo data, it provides a compelling basis for further investigation into miR-148b as a potential therapeutic target or biomarker in renal cell carcinoma.
Summary updated